Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue SUPPL. 2, 1996, Pages 7-12

  Hirsh, Jack ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0029852739     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Frydman A, L Bara, Y Leroux, M Woler, F Chaliac, M Samama: The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg. J Clin Pharmacol 28:609-618, 1988.
2. Briant L, C Caranobe, S Saivin, B Byrou, G Houin, B Boneu: Unfractionated heparin and CY216. Pharmacokinetics and bioavailabilities of the anti-Factor Xa and IIa. Effects of IV and subcutaneous injection in rabbits. Thromb Haemostas 61:348-353, 1989.
3. Bratt G, E Tornebohm, L Widlund, D Lockner: Low molecular weight heparin (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42:613-620, 1986.
4. Matzsch T, D Bergqvist, U Hedner, P Ostergaard: Effect of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemostas 57:97-101, 1987.
5. Bara L, MM Samama: Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 543:65-72, 1988.
6. Bradbrook ID, HN Magnani, HC Moelker, PJ Morrison, J Robinson, HF Rogers, RG Spector, T Van Dinther, H Wijnard: ORG 10172: A low molecular weight heparinoid anticoagulant with a long half life in man. Br J Clin Pharmacol 23:667-675, 1987.
7. Handeland GF, GF Abildgaard, U Holm, KE Arnesen: Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39:107-112, 1990.
8. Holm HA, B Ly, GF Handeland, U Abildgaard, KE Arnesen, P Gottschalk, V Høeg, M Aandahl, K Haugen, F Laerum: Subcutaneous heparin treatment of deep vein thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 16(suppl 2):30-37, 1986.
9. Faivre R, E Neuhart, Y Kieffer, F Toulemonde, JP Bassand, JP Maurat: Subcutaneous administration of a low molecular weight heparin CY222 compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. (Abst.) Thromb Haemostas 58(suppl):430:1987.
10. Bratt G, E Tornebohm, S Granqvist, W Aberg, D Lockner: A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis (DVT). Thromb Haemostas 54:813-817, 1985.
11. Bratt G, W Aberg, M Johansson, E Tornebohm, S Granqvist, D Lockner: Two daily subcutaneous injection of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemostas 64:506-510, 1990.
12. Duroux P, A Beclere: A randomised trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemostas 65:251-256, 1991.
13. Simonneau G: Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemostas 65(suppl):754 (Abst), 1991.
14. Prandoni P, AWA Lensing, HR Buller, M Carta, A Cogo, M Vigo, D Casara, A Ruol, JW Ten Cate: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441-445, 1992.
15. Lopaciuk S, AJ Meissner, S Filipecki, K Zawilska, J Sowier, L Ciesielski, M Bielawiec, S Glowinski, E Czestoehowska: Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemostas 68:14-18, 1992.
16. Hull RD, GE Raskob, GF Pineo, D Green, AA Trowbridge, CH Elliott, RG Lerner, J Hall, T Sparling, HR Brelleil: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975-982, 1992.
17. Lensing AWA, MH Prins, BL Davidson, J Hirsh: Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis. Arch Intern Med 155:601-607, 1995.
18. Levine M, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, AG Turpie, C Demers, M Kovacs, W Geerts, J Kassis, L Desjardins, J Cusson, M Cruickshank, P Powers, W Brien, S Haley, A Willan: A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 334:677-681, 1996.
19. Koopman MMW, P Prandoni, F Piovella, PA Ockelford, DPM Brandjes, J van der Meer, AS Gallus, G Simonneau, CH Chesterman, MH Prins, PMM Bossuyt, H de Haes, AGM van den Belt, L Sagnard, P d' Azemar, HR Büller, for the TASMAN Study Group: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334:682-687, 1996.
20. Pini M, S Alello, C Manotti, C Pattacini, R Quintavalla, T Poli, A Tagliaferri, AG Dettori: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostas 72:191-197, 1994.